Results 221 to 230 of about 1,375,213 (331)

IL-23 drives uveitis by acting on a population of tissue-resident entheseal T cells. [PDF]

JCI Insight
Hedley R, Ward A, Chu CJ, Coupland SE, Kiriakidis S, Taylor PC, Dakin SG, ORBIT Research Consortium, Buckley CD, Sherlock J, Dick AD, Copland DA.   +11 more
europepmc   +1 more source

Cutting Edge: IFN-  Is a Negative Regulator of IL-23 in Murine Macrophages and Experimental Colitis

, 2020
Shehzad Z. Sheikh, Katsuyoshi Matsuoka, Taku Kobayashi, Fengling Li, Tara C. Rubinas, Scott E. Plevy   +5 more
openalex   +1 more source

IL-23 promotes arthritic and inflammatory pain [PDF]

Nature Reviews Rheumatology, 2020
openaire   +2 more sources

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Impact of IL-23 in prostate cancer

Asian Journal of Andrology, 2022
openaire   +3 more sources

Aggressive prostate cancer is associated with pericyte dysfunction

Molecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera   +11 more
wiley   +1 more source

Real-World Effectiveness of Risankizumab in Crohn's Disease: Outcome Data for an IL-23 Inhibitor from the Middle East. [PDF]

Crohns Colitis 360
Alzaabi MN, Swaid TK, Ahmed HA, Alahmad MA, Omar NM, Chitra Kumar KK, Ahmed EF, Malik TA, Quraishi MN.   +8 more
europepmc   +1 more source

Generation of IL-23 Producing Dendritic Cells (DCs) by Airborne Fungi Regulates Fungal Pathogenicity via the Induction of TH-17 Responses

, 2020
Georgios Chamilos, Dipyaman Ganguly, Roberto Lande, Josh Gregorio, Stephan Meller, William E. Goldman, Michel Gilliet, Dimitrios P. Kontoyiannis   +7 more
openalex   +1 more source

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

Molecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard, Cristina Mitric, Melanie Care, Tracy L. Stockley, Raymond H. Kim, Jeanna McCuaig, Blaise Clarke, Laura Ranich, Clare Sheen, Sarah E. Ferguson, Liat Hogen, Taymaa May, Marcus Q. Bernardini   +12 more
wiley   +1 more source

Safety and efficacy of IL-23 inhibitors in patients with moderate to severe ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Int J Colorectal Dis
Amin HM, Hasan S, Abukhater R, Lilley R, Atique A, Shoaib MS, Albustanji Q, Sadique H, Khalid SM, Hasan A, Majeed S, Shahzad MA, Shahzad M, Ahmed M, Ahmed R, Gardezi SA.   +15 more
europepmc   +1 more source